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Background: A retrospective analysis is performed to determine if pre-treatment [18 F]-2-fluoro-2-deoxyglucose
positron emission tomography/computed tomography (FDG PET/CT) image derived parameters can predict radiation
pneumonitis (RP) clinical symptoms in lung cancer patients.
Methods and Materials: We retrospectively studied 100 non-small cell lung cancer (NSCLC) patients who underwent
FDG PET/CT imaging before initiation of radiotherapy (RT). Pneumonitis symptoms were evaluated using the Common
Terminology Criteria for Adverse Events version 4.0 (CTCAEv4) from the consensus of 5 clinicians. Using the cumulative
distribution of pre-treatment standard uptake values (SUV) within the lungs, the 80th to 95th percentile SUV values
(SUV80 to SUV95) were determined. The effect of pre-RT FDG uptake, dose, patient and treatment characteristics on
pulmonary toxicity was studied using multiple logistic regression.
Results: The study subjects were treated with 3D conformal RT (n = 23), intensity modulated RT (n = 64), and
proton therapy (n = 13). Multiple logistic regression analysis demonstrated that elevated pre-RT lung FDG uptake
on staging FDG PET was related to development of RP symptoms after RT. A patient of average age and V30 with
SUV95 = 1.5 was an estimated 6.9 times more likely to develop grade ≥ 2 radiation pneumonitis when compared to
a patient with SUV95 = 0.5 of the same age and identical V30. Receiver operating characteristic curve analysis
showed the area under the curve was 0.78 (95% CI = 0.69 – 0.87). The CT imaging and dosimetry parameters were
found to be poor predictors of RP symptoms.
Conclusions: The pretreatment pulmonary FDG uptake, as quantified by the SUV95, predicted symptoms of RP in
this study. Elevation in this pre-treatment biomarker identifies a patient group at high risk for post-treatment
symptomatic RP.
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Radiation pneumonitis (RP), an inflammatory reaction
within lung tissue secondary to radiation damage [1,2],
is a severe and potentially fatal complication of thoracic
radiotherapy (RT). Symptoms of RP include dyspnea,
non-productive cough, shortness of breath, fever, and
changes in pulmonary function. RP-associated mortality
has been noted in the treatment of many cancers including
breast [3], esophageal [4,5], lung [6,7], and mesothelioma* Correspondence: tguerrero@mdanderson.org
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unless otherwise stated.[8-10]. Furthermore, the mortality rate among non-small
cell lung cancer (NSCLC) patients experiencing severe
RP symptoms requiring hospitalization approaches 50%
[11]. The variability of RP symptoms onset and intensity
with respect to patient specific radiation dose, irradiated
lung volume, and pulmonary function has made past
prognostication efforts futile [12]. Treatment toxicity
including RP remains a barrier to radiation dose escalation
in lung cancer [13]. Because RP plays such an important
role in defining the therapeutic index for lung cancer,
clearly there remains a significant need for patient specific
prognostication.Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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[14-16] and chemotherapy type [3,7,17] have been shown
to affect occurrence and degree of RP. Another such
factor, interstitial pneumonitis (IP) on pretreatment com-
puted tomography (CT) scans, has been shown to predict
an increased risk of symptomatic RP [18-20]. Makimoto
et al. [18] found that in patients with primary lung cancer,
pre-existing lung disease evidenced by pretreatment radio-
graphic changes was associated with a higher incidence of
RP (47.1% vs. 5.3%, p < 0.001). Another study showed a
correlation between severe RP and pretreatment IP foci in
the lung periphery on CT, although exclusion of patients
with IP from receiving SBRT led to a reduction in the
incidence of severe RP from 18.8% to 3.5% (p = 0.042) in
subsequent cases [20]. Additionally, among 106 patients
treated with thoracic RT, pretreatment interstitial changes
on CT were associated with a higher incidence of grade ≥ 3
RP (26% versus 3%, p < 0.001) [19]. CT scans and x-rays
are not the only method to detect pulmonary inflamma-
tory processes. With [18F]-2-fluoro-2-deoxyglucose posi-
tron emission tomography (FDG PET) imaging, pulmonary
inflammation manifests as enhanced FDG uptake, thereby
allowing for the quantitative assessment of pneumonitis
[21-23]. Recently, Petit et al. [24] performed a retrospective
study of 101 NSCLC patients to evaluate the correlation
between symptomatic RP and pre-RT FDG PET/CT evi-
dence of pulmonary inflammation. They report that the
95th percentile of the standard uptake value (SUV95)
within the lungs was predictive of RP on multivariate
analysis (p = 0.016), suggesting that the SUV95 can be
used to screen for RP risk during thoracic RT treatment
planning [24].
In this retrospective study, pre-RT FDG PET/CT image
derived factors are analyzed as potential prognostic bio-
markers of symptomatic RP in NSCLC patients, testing
the findings reported by Petit et al. [24]. We hypothesize
that these pre-RT image derived factors identify individ-
uals at high risk for symptomatic RP.
Methods and Materials
Patient population
The study population consisted of 100 non-small cell lung
cancer patients who were treated in the Department of
Radiation Oncology at the University of Texas M. D.
Anderson Cancer Center between July 2004 and May
2012, and who had their staging PET/CT imaging within
90 days prior to the start of radiotherapy. All study sub-
jects had biopsy-proven NSCLC, and their imaging studies
are available in the electronic medical records. Patient
characteristics were obtained for each study subject in-
cluding age, sex, disease stage, tumor location, smoking
history, tumor histologic type, radiation planning, interval
between staging PET and RT, concurrent chemotherapy,
and pre-existing lung disease (as assessed by FEV1 andDLCO parameters). Patient identifiers were removed in ac-
cordance with a retrospective study protocol (PA11-0801)
approved by the MD Anderson Institutional Review Board.
Waiver of informed consent was approved by the Institu-
tional Review Board for this retrospective study protocol.
18F-FDG PET/CT imaging
Patients fasted 6 hours prior to the 18F-FDG PET/CT
imaging session and were required to have blood glucose
levels < 120 mg/dL. Intravenous injection of 629 (range:
550 – 740) MBq of 18F-FDG occurred 60 (range: 52–110)
minutes prior the image acquisition. The General Electric
Discovery ST PET/CT scanner (GE Medical Systems,
Waukesha, WI) was used to acquire the 18F-FDG PET/
CT images. Patients were instructed to breath normally
during the PET emission acquisition. The 18F-FDG PET
images included in this study acquired before 2006 were
attenuation corrected using a non-contrast mid-inspiratory
breath-hold CT, and those after used a respiratory averaged
CT [25]. PET/CT images were acquired from mid-thigh
to the skull base with arms raised. Standard uptake
values (SUV) were calculated from the attenuation cor-
rected 18F-FDG PET emission images using the following
equation [26]:
StandardUptakeValue¼
18F‐FGDcount ratepermLbodyweight gmð Þ
decay corrected18F‐FDG injected dose Bqð Þ
ð1Þ
Radiation treatment planning
Treatment planning for megavoltage x-ray cases was per-
formed using the Pinnacle3 version 7.6c or 8.0u treatment-
planning system (Philips Medical Systems, Andover, MA).
Proton therapy cases were planned using the respiratory
averaged CT and the Eclipse treatment planning system
(Varian Medical Systems, Palo Alto, CA). Gross target de-
lineation and margin generation were performed in a con-
sistent manner, as previously reported by our group [27].
Radiation dose was calculated using either free-breathing
treatment planning CT data (most cases) or averaged CT
data obtained from the treatment planning 4D CT image
set [28,29]. All treatment plans and field arrangements were
prospectively reviewed in quality assurance meetings in
which consensus was obtained according to each patient's
clinical circumstances. The radiation dose distributions
were all calculated using lung heterogeneity corrections.
The mean lung dose (MLD) and the percentage of lung
volume irradiated to above 5 Gy or CGE (V5), 10 Gy or
CGE (V10), 20 Gy or CGE (V20), and 30 Gy or CGE (V30)
were used as dosimetric parameters to represent the lung
volumes irradiated.
For proton cases, all plans were designed for passive
scattering delivery. Using a constant relative biological
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converted to 60Co Gray Equivalents (CGE).
Clinical Toxicity and Radiation Parameters
Pneumonitis was scored using the National Cancer Institute
Common Terminology Criteria for Adverse Events version
4 (CTCAE v4). All patient documents were used in the
scoring, including consultation notes, radiographic im-
ages, clinic notes, summaries and scanned outside medical
records until 6 months after completing radiation. A
simple group consensus of 5 clinicians was used for each
score. Cases were reviewed until all discrepancies were re-
solved by unanimous agreement. Clinically symptomatic
pneumonitis was defined as grade 2 or higher. All patients
with RP scores > 1 had radiographic findings consistent
with RP within the radiotherapy treatment field. These
findings were evident on follow-up CT imaging and/or
PET/CT.
Image analysis
The treatment plan and PET/CT images for each patient
were processed and evaluated using custom MATLAB
software (v2011a, Mathworks, Inc.). Lung regions of inter-
est (ROIs) were segmented semi-automatically using histo-
gram segmentation of the lung parenchyma and removal of
the central airway by connectivity. PET spill-over artifacts
(Figure 1) attributable to liver, heart, or tumor activities
were manually contoured for exclusion from the seg-
mented lung volume. Attenuation cold-spot artifacts atFigure 1 Lung segmentation and removal of PET spill-over activity ar
region growing were used to delineate the set of lung voxels on the pre-t
ROI were manually contoured for exclusion. Top row: lung ROI shown (a) b
Bottom row: the region of exclusion due to tumor is show in red (c) beforethe diaphragm surface [30] were also manually removed.
The effect of manual editing on the lung ROI and subse-
quent analysis was assessed according to repeat image
segmentation performed by 3 independent secondary
reviewers in a subsample of 10 patients (10% of all cases).
The primary reader binary lung ROI was used in subse-
quent analyses.
Pretreatment PET/CT analysis
Using the pretreatment FDG PET images, the SUV of all
voxels within the lung ROI were binned into histograms,
and the mean SUV (SUVmean), the standard deviation of
the SUV (SUVSD), and the maximum SUV (SUVmax) were
calculated as described in Petit et al. [24]. A cumulative
probability distribution was constructed from each histo-
gram (Figure 2) and used to determine the 80th, 90th, and
95th percentiles of the SUV distribution, hereafter des-
ignated: SUV80, SUV90, and SUV95, respectively. To de-
termine if pre-treatment CT density could predict RP, the
cumulative density parameters mentioned above were also
calculated for Hounsfield Unit (HU) of the CT scan: the
HUmean, HUSD, HUmax, HU80, HU90, and HU95.
Statistical Analysis
Categorical variables (i.e., gender, tumor stage, tumor
location, tumor histologic type, radiotherapy modality,
chemotherapy status, smoking status, GOLD classification)
were summarized using frequency tables; evaluated for as-
sociation with symptomatic (grade ≥ 2) RP using Pearson’stifacts. Semi-automated histogram segmentation and morphological
reatment staging PET/CT studies. PET spill-over activities into the lung
efore and (b) after manual correction of cardiac spill-over activity.
and (d) after manual correction.
Figure 2 Quantifying the SUV95. SUV values within the lung are determined by semi-automated segmentation of the lung voxels from the
pre-treatment staging PET/CT study (left). The cumulative distribution of SUV values is constructed from the voxel values within the lung ROI. The
80th, 90th, and 95th percentiles are obtained from these distributions to yield the corresponding SUV80, SUV90, and SUV95. The SUV95 is depicted
graphically (right) for the example case, with the ROI≥ SUV95 shown superimposed (middle).
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interval between radiotherapy and PET imaging were
summarized by median and range; evaluated for association
with symptomatic (grade ≥ 2) radiation pneumonitis using
Mann–Whitney U tests. Univariate logistic regression
analyses were used to predict symptomatic (grade ≥ 2) RP
as functions of pre-RT pulmonary and dosimetry charac-
teristics (i.e., SUV, HU, MLD, irradiated volume, FEV1%,
DLCO%). Post-hoc application of the sequentially rejective
Bonferroni method [31] was used to adjust for multiplicity
among the six SUV analyses.
Multiple logistic regression inference used stepwise
backward model selection based on Akaike information
criterion [32]. Results are provided for the best subset of
predictors (SUV95, V30, age). Partial effects were evaluated
for significance using two-sided Wald tests. Nagelkerke’s
coefficient of multiple determination [33] is used to report
the proportion reduction in error variation obtained by
incorporating the predictors. The resultant receiver oper-
ating characteristic (ROC) curve is provided with Delong’s
95% confidence interval [34] for the area under the curve
(AUC) and Youden’s optimal [35] specificity and sensitiv-
ity. Additionally, recursive partitioning analysis [36] was
used to formulate a binary classification tree based upon
both SUV95 and V30. Kaplan-Meier curves were used to
compare time to radiation pneumonitis symptom develop-
ment among the observed terciles of SUV95 (SUV95 < 0.99,
0.99 ≤ SUV95 < 1.2, SUV95 ≥ 1.2); Cox proportional hazard
regression was used to evaluate the rate of RP symptom
development as a function of SUV95 adjusted for patient
and treatment characteristics. Stepwise backward model
selection used generalized Akaike information criterion
[29]. Results are provided for the best subset of predictors
(SUV95, V30, age). Inter-reviewer variability in determin-
ation of SUV95 was assessed for 3 independent reviewers
in a subsample of 10 patients; 95% limits of agreement
were estimated using one-way mixed effects ANOVA [37].The resultant Bland-Altman plot [38] is provided. All
tests were two sided with α = 0.05 to confer statistical
significance. All plots and analyses were performed using
the statistical software R (R Development Core Team,
http://www.r-project.org) version 3.0.
Results
Patient Characteristics and RP Symptoms
An overview of the 100 study subjects and their char-
acteristics is presented in Tables 1 and 2. Of the study
participants, 14 (14%) were treated with RT alone while
86 (86%) received concurrent chemo-radiation (che-
moRT). The prescription dose range was 36 to 74 Gy
(median 66) over 12–37 fractions (median 35). The
mean lung dose was between 2.88 and 29.43 Gy (me-
dian 17.86 Gy). Consensus CTCAEv4 RP symptom
scores were: 10 patients (10%) had no evidence of re-
spiratory symptoms or imaging changes (grade 0), 31
patients (31%) had only radiographic or mild respira-
tory symptoms without requirement of intervention
(grade 1), 27 patients (27%) had post-RT respiratory
symptoms affecting the extended activities of daily liv-
ing (grade 2), 23 (23%) required oxygen (grade 3), 1
(1%) respiratory failure requiring intubation (grade 4)
and, 8 (8%) died from respiratory compromise (grade 5).
A total of 60% of the patients experienced symptomatic
RP.
The patient demographics, stage, tumor location, tumor
histology, treatment type and smoking history are reported
in Table 1 for the total and symptomatic (CTCAEv4 RP
grade ≥ 2). Treatment characteristics and outcomes are
listed in Table 2. The data lacked significant evidence
to conclude that the presence of symptomatic RT was
associated with other clinical factors including tumor
stage, histology, location, type of RT, or preexisting
lung disease based on FEV1 parameters, as well as any
CT-derived imaging parameters.
Table 1 Patient Characteristics
Parameter Total (%) Symptomatica N (%) p-value




Symptomatic (IQR) 59.5-73 yrs
Asymptomatic (IQR) 54-66 yrs
Stageb 0.36
I 6 (6) 1 (16.7)
II 5 (5) 4 (80)
III 78 (78) 48 (61.5)
IV 11 (11) 6 (54.5)
Tumor locationb 0.97
LLL 15 (15) 10 (66.7)
LUL 25 (25) 15 (60)
RLL 9 (9) 6 (66.7)
RML 6 (6) 4 (66.7)
RUL 45 (45) 24 (53.3)
Tumor histologyb 0.66
Adenocarcinoma 57 (57) 30 (52.6)
Neuroendocrine 1 (1) 1 (100)
Non-small 18 (18) 13 (72.2)
Squamous 24 (24) 15 (62.5)
Treatment typeb 0.89
IMRT 64 (64) 35 (54.7)
Proton 13 (13) 9 (69.2)
3D Conformal 23 (23) 15 (65.2)
Chemotherapy status 0.66
Concurrent 86 (86) 52 (60.5)
RT alone 14 (14) 7 (50)
Smoking historyb 0.92
Currently 28 (28) 15 (53.6)
Former 66 (66) 40 (60.6)
Never 6 (6) 4 (66.7)
Interval between staging PET/CT and start of RT 0.65
Median (range) in days 18 (3–69) 15 (3–69)
aSymptomatic status: CTCAEv4 RP grade ≥ 2.
bYates’ continuity correction applied.
IQR: Inter-quartile range.
Note: Hypothesis testing for association used the Mann–Whitney U test for
continuous predictors; Pearson’s chi-squared test for marginal homogeneity for
categorical predictors.
Table 2 Treatment characteristics and outcomes
Treatment dose (Gy or CGE)
Range (median) 36 – 74 (66)
Mean lung dose (Gy or CGE)
Range (median) 2.88 – 29.43 (17.86)







Pre-RT pulmonary function test, range (median)
FEV1 (%) 30 – 124 (72.5)
DLCO (%) 23 – 125 (64)
aSymptomatic status: CTCAEv4 RP grade ≥ 2.
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Age was the only non-modifying factor found to be
significantly associated with the development of symp-
tomatic RP using the Mann–Whitney U hypothesis test.
Univariate logistic regression analyses are summarized inTable 3. Odds of grade ≥ 2 radiation pneumonitis in-
creased with SUVmean, SUVSD, SUV80, SUV90, and SUV95
as well as V30. SUV95 was the most significant independ-
ent predictor of post-radiation lung toxicity (p < 0.0049).
In addition, significant partial effects were observed for
SUV95 (p < 0.0027), V30 (p < 0.007), and age (p < 0.0026)
in the multiple logistic regression analysis provided in
Table 4. For a given age and value of V30, each incre-
mental increase in SUV95 of size 0.1 was associated with
a 1.5-fold increase (95% CI: 1.1 – 1.9, p < 0.0027) in the
partial odds of symptomatic RP. A patient of average
age (64) and V30 (23.8) with a value of SUV95 = 1.2 (1.5)
is 1.4 (6.9) times more likely to develop symptomatic RP
when compared to a patient presenting with SUV95 = 1
(0.5) of the same age and identical V30. Additionally, the
partial odds of symptomatic RP increased 2.2-fold with
each increase in age of 1 year and 1.1-fold with each
unit increase in V30, respectively.
Receiver Operating Characteristic (ROC) analysis de-
rived from pre-treatment SUV95, V30, and age to predict
symptomatic (grade ≥ 2) radiation pneumonitis is shown
in Figure 3. The area under the ROC curve derived from
the multiple logistic regression inference was found to
be 0.78 (95% CI = 0.69 – 0.87) with Youden’s optimal
sensitivity = 92% and specificity = 51%. The distribution
of symptomatic and asymptomatic is plotted against
SUV95 and V30 in Figure 4. Recursive partition analysis
for classification of RP symptoms using pre-treatment
SUV95 and V30 in 3 cohorts is also shown. The optimal
partition (assuming identical misclassification costs)
derives from classifying patients with pre-treatment
SUV95 > 0.949 or V30 > 27.14 as symptomatic, patients
with SUV95 < 0.949 and V30 < 27.14 as asymptomatic.
The joint classification tree results in sensitivity = 98%
and specificity = 37%.
Figure 3 Receiver operating characteristics curve for RP
symptoms. Receiver Operating Characteristic (ROC) curve (solid)
derived from pre-treatment SUV95, V30, and age to predict symptomatic
(grade ≥ 2) radiation pneumonitis. The area under the ROC curve
derived from the multiple logistic regression inference was found to
be 0.78 (95% CI: 0.69 – 0.87) with Youden’s optimal sensitivity = 92%
and specificity = 51%.
Table 3 Logistic regression analysis for grade ≥ 2 RP
Predictor Coefficient SE Odds ratio (95% CI) p-value
SUVmax 0.16 0.095 1.2 (0.97, 1.4) 0.10
SUVmean 0.34 0.15 1.4 (1.1, 1.9) <0.02
a,b
SUVSD
1 1.5 0.54 4.4 (1.5, 12.8) <0.0057a,b
SUV80
1 0.31 0.13 1.4 (1.1, 1.7) <0.013a,b
SUV90
1 0.33 0.12 1.4 (1.1, 1.7) <0.0061a,b
SUV95
1 0.33 0.12 1.4 (1.1, 1.7) <0.0049a,b
HUmax
2 0.013 0.02 1 (0.97, 1.1) 0.51
HUmean
2 −0.09 0.34 0.91 (0.47, 1.8) 0.79
HUsd
2 −0.18 0.93 0.83 (0.14, 5.1) 0.85
HU80
2 −0.07 0.37 0.93 (0.46, 1.9) 0.85
HU90
2 −0.10 0.32 0.91 (0.48, 1.7) 0.76
HU95
2 −0.10 0.32 0.91 (0.48, 1.7) 0.76
MLD3 0.88 0.58 2.4 (0.78, 7.5) 0.13
V5
3 0.15 0.53 1.2 (0.41, 3.3) 0.77
V10
3 0.58 0.55 1.8 (0.6, 5.3) 0.30
V20
3 1.1 0.63 3 (0.87, 10.5) 0.081
V30
3 1.2 0.57 3.3 (1.1, 10.3) 0.035
FEV1(%)2 −0.13 1 0.88 (0.12, 6.6) 0.897
DLCO(%)2 −1.2 1.1 0.31 (0.034, 2.9) 0.31
1Scaled by 10.
2Scaled by 0.01.
3Log-transformation applied to improve model fit.
aSequentially rejective Bonferroni method applied to adjust for multiplicity at
the α = 0.05 familywise significance level.
bOdds of grade ≥ 2 radiation pneumonitis increased with SUVmean, SUVSD,
SUV80, SUV90, and SUV95.
Note: SE = standard error of the estimated coefficient parameter; CI = confidence
interval for the odds ratio; p-values derived from two-sided hypothesis tests using
Wald chi-square.
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Pneumonitis
Among patients who developed symptomatic RP, the aver-
age time from start of RT to symptomatic development was
observed to be 3.5 months for patients with SUV95 > 0.99Table 4 Multiple logistic regression analysis for grade ≥ 2
RP (N = 100)
Predictor Coefficient SE Odds ratio (95% CI) p-value
Intercept −6.1 1.7
SUV95
a 0.40 0.13 1.5 (1.1-1.9) <0.0027
Ageb 0.79 0.26 2.2 (1.3-3.7) <0.0026
V30 0.09 0.034 1.1 (1–1.2) <0.007
aScaled by 10.
bStandardized age was used with origin corresponding to the mean of 64.
Note: SE = standard error of the estimated coefficient parameter; CI = confidence
interval for the odds ratio; Stepwise backward model selection based on Akaike
information criterion was used; Symptomatic radiation pneumonitis was
conditionally independent of tumor location, stage, histology, smoking status,
MLD, and RT modality in the presence of SUV95, V30, and age; p-values derived
from two-sided hypothesis tests using Wald chi-square; significant partial effects
suggest that the odds of symptomatic radiation pneumonitis increased with
SUV95, V30, and age; Nagelkerke coefficient of multiple determination R
2 = 0.32.and 4.5 months for patients with SUV95 < 0.99. Kaplan-
Meier curves were constructed to compare time to
radiation pneumonitis symptoms among subsets of
patients within observed terciles of SUV95 (SUV95 < 0.99,
0.99 ≤ SUV95 < 1.2, SUV95 ≥ 1.2). Figure 5 shows that
patients with SUV95 ≥ 1.2 developed symptoms at a rate
2.39 (1.19, 4.82) times the rate of patients with SUV95 < 0.99,
while patients with 0.99 ≤ SUV95 < 1.2 developed symptoms
at a rate 2.25 (1.12, 4.52) times greater.
Additionally, multiple Cox proportional hazards regres-
sion was used to evaluate the association between SUV95
and time to development of symptomatic RP, adjusted for
age and V30 (Table 5). The odds of developing symptom-
atic RP within a given duration of time increased with
SUV95, age, and V30. SUV95 contributed the most sig-
nificant partial effect (p < 0.002). Given age and V30, each
incremental 0.1 increase in SUV95 was associated with a
1.2-fold increase (1.1, 1.3) in the partial hazard rate of RP
symptom development.
Inter-reviewer agreement for acquisition of SUV95
Inter-reviewer agreement among three independent re-
viewers for determination of SUV95 using a representative
10% of all cases (10 subsampled patients) is plotted in
Figure 6. Inter-reviewer deviation was within approximately
6% of the reviewer average at the α = 0.05 significance level.
Figure 5 Kaplan-Meier curves for pre-treatment SUV95. Time
to radiation pneumonitis symptoms is compared among subsets
of patients within observed terciles of SUV95 (SUV95 < 0.99, 0.99
≤ SUV95 < 1.2, SUV95 ≥ 1.2). Right-censored observations are marked
by +. The hazard ratios (HR) and corresponding 95% confidence
intervals for comparing between the (2nd and 1st) terciles; and
(3rd and 1st) terciles follow as 2.25 (1.12, 4.52) and 2.39 (1.19, 4.82),
respectively. Median time to symptoms for patients with SUV95 ≥ 0.99
was 101 days.
Table 5 Cox proportional hazards regression analysis for
time to radiation pneumonitis symptoms (N = 100)
Predictor Coefficient SE Hazard ratio (95% CI) p-value
SUV95
a 0.18 0.057 1.2 (1.1-1.3) <0.002
Ageb 0.34 0.14 1.4 (1.1-1.8) 0.013
V30 0.05 0.02 1.1 (1–1.1) 0.011
aScaled by 10.
bStandardized age was used with origin corresponding to the mean of 64.
Note: SE = standard error of the estimated coefficient parameter; CI = confidence
interval for the hazard ratio; Stepwise backward model selection based on
generalized Akaike information criterion was used; symptomatic radiation
pneumonitis was conditionally independent of tumor location, stage, histology,
smoking status, treatment type, and MLD in the presence of SUV95, V30, and age;
p-values derived from two-sided hypothesis tests using Wald chi-square; the rate
of symptom development was increased significantly with SUV95, V30, and age.
Figure 4 Classification of symptomatic and asymptomatic RP
against SUV95 and V30. Recursive partition analysis for classification
of RP symptoms using pre-treatment SUV95 and V30 for N = 100 lung
cancer patients results in 3 cohorts. The optimal partition derives
from classifying patients with pre-treatment SUV95 > 0.949 or V30 > 27.14
as symptomatic, and those with SUV95 < 0.949 and V30 < 27.14 as
asymptomatic. The joint classification tree results in sensitivity = 98%
and specificity = 37%.
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inherent subjectivity associated with the manual interven-
tion to remove PET spill-over activity artifacts (Figure 1)
and SUV cold spot artifacts at the lung/diaphragm inter-
face due to respiration. While deviation on the order of
6% is not innocuous given the magnitude of association
between the risk of RP and the pre-treatment SUV95,
this represents the 95% limit of agreement based upon a
subset of 10 patients. Thus we expect on average that
inter-reader deviation would be on the order of ± 3%,
which corresponds to only a 0.88 to 1.12-fold change in
the odds of symptomatic RP.
Discussion
In this study, we demonstrated the potential of a quantita-
tive image derived prognostic biomarker, the SUV95, for
the pre-treatment identification of NSCLC patients at highFigure 6 Bland-Altman plot for inter-reviewer agreement in the
determination of pre-treatment lung SUV95. Observed and
expected percentage deviation from mean SUV95 in a subsample of
10 patients assessed by three independent reviewers. One-way
mixed effects ANOVA obtains 95% confidence boundaries = ±6.10%.
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a quantitative assessment of pre-existing pulmonary in-
flammation [22,39], which in turn predicts the individual
subject’s ability to tolerate thoracic radiation without tox-
icity. This study, which includes a mixture of proton and
photon treated lung cancer cases, replicates the finding of
Petit et al. [24] who studied a photon-only treated NSCLC
cohort. Dehing et al. [40] previously analyzed data from a
photon-only treated cohort of 438 patients with NSCLC
or SCLC to assess predictive value of patient characteris-
tics and dosimetric parameters associated with dyspnea
following thoracic chemo-radiotherapy. Univariate models
with V20 (mean: 21%, SD: 7.3%) or MLD (mean: 13.5 Gy,
SD: 4.5 Gy) both yielded AUC of 0.47. The final multivari-
ate model, which included WHO-performance status,
smoking status, forced expiratory volume, age, and MLD,
yielded an AUC of 0.62 (95% CI: 0.55-0.69). However, the
authors cite that baseline dyspnea scores were not avail-
able to rule out the possibility that patients with low FEV1
values already had an elevated dyspnea score prior to
treatment. The current study supports the previous find-
ings by Dehing et al. that a combination of patient-related
factors and dosimetric parameters, namely the SUV95,
V30, and age, is better suited as a prognostic indicator for
symptomatic outcomes following thoracic radiotherapy.
Pretreatment FDG PET/CT imaging is already routinely
obtained for staging of NSCLC [41-43] and has an emer-
ging role in target delineation for radiotherapy treatment
planning for NSCLC [44,45]. The SUV95, computed from
imaging studies already obtained for staging and treatment
planning, can be used to stratify toxicity risk without in-
curring additional cost.
Notably, the significant association between Hounsfield
Unit derived parameters and increase in dyspnea reported
by Petit et al. [24] did not hold in the current analysis.
The difference may arise due to the difference in CT ac-
quisition methods between studies. Although Petit et al.
describe both respiratory gated 4D-CT and low-dose CT
with intravenous contrast for each patient, it is not clear
which CT image set was utilized to calculate the lung
region of interest (ROI) Hounsfield Unit values. In this
study, Hounsfield Unit ROI parameters were derived
utilizing the radiotherapy treatment planning CT, which
was a mix of either free-breathing CT (FB-CT) or 4D-CT.
Other imaging modalities have been utilized to estimate
the pretreatment symptomatic RP risk. The relationship
between the radiation dose distribution and subsequent
RP has been well studied and is summarized nicely by
Rodrigues et al. [6]. Single photon emission computed
tomography (SPECT) perfusion imaging has been utilized
to demonstrate radiation-induced lung toxicity [46,47],
showing a nearly linear loss of perfusion with radiation
dose. Kocak et al. [12] prospectively tested RP prediction
models based on pulmonary perfusion and radiation dosedistributions using models built from one data set and
tested on two other data sets. Those models were unable
to segregate patients into high and low risk of RP groups
in the test data sets. Others have utilized pretreatment
ventilation imaging to predict RP in single cohort retro-
spective studies [48]; however the ROC AUC was small.
Hope et al. [49] developed a 3-parameter model (from the
tumor superior-inferior relative position, maximum dose,
and dose to the hottest 35% of the lung volume), which
was tested using a separate data set (RTOG 9311) by
Bradley et al. [50] and performed poorly. The STRIPE
meta-analysis of pneumonitis after chemoradiotherapy for
lung cancer [7] found that concurrent paclitaxel, age, and
V20 were significant predictive factors with odds ratios of
5.58, 1.38, and 1.07 respectively. Paclitaxel is a radiosensi-
tizer of lung tissue [3,51] that can cause pneumonitis even
when used alone [52-54]. The SUV95 quantifies pre-existing
pulmonary inflammation, the severity of which may reflect
the underlying individual propensity toward an inflamma-
tory response.
For lung cancer clinical trials involving thoracic radiation
with pulmonary toxicity as an end-point, the SUV95 can be
utilized to (1) ensure equally balanced arms or (2) exclude
those who appear to have a nearly 100% certainty of devel-
oping symptomatic pulmonary toxicity. An analysis of a
prospective clinical trial conducted by the Radiotherapy
Oncology Group (RTOG) indicates higher biologically
effective doses of radiotherapy are associated with im-
proved outcomes [55]. However, the recently completed
prospective study RTOG 0617 found no advantage as
well as increased toxicity in the higher dose arm [13].
Biomarkers such as the SUV95 may be used for stratifica-
tion to enroll only low RP risk study subjects. The SUV95
can also be utilized to identify a subgroup at high risk for
the development of RP symptoms for clinical trials study-
ing RP-prevention drugs. A cohort with an expected high
incidence of RP would power a drug RP prevention trial
using fewer study subjects to measure a reduction in RP
toxicity events.
Our study was limited by the retrospective nature of this
analysis, which could contain inherent biases that we are
not aware of despite our best efforts to control for poten-
tial confounders. The 3D-CRT patients were treated in
an earlier time period, which may have accounted for
increased toxicities with less modern imaging and treat-
ment planning techniques. Additionally, the 3D PET im-
ages were not acquired with motion correlation [56], thus
contributing to spatial blurring and spill-over activity
artifacts that required manual intervention processes
to exclude from data analysis. Pneumonitis grade was
scored using the medical record rather than standardized
questionnaires. A prospective study addressing the pulmon-
ary toxicity should include standardized survey such as the
St. George Respiratory Questionnaire [57].
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In the present study, patients with high FDG uptake
prior to treatment were more likely to develop symptom-
atic RP. Our findings may be used to identify patients at
high risk for radiation-induced lung damage so that inter-
ventions can be developed and fatal RP avoided.
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